Zentalis Pharmaceuticals, Inc. (ZNTL)
ZNTL Stock Price Chart
Explore Zentalis Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze ZNTL price movements and trends.
ZNTL Company Profile
Discover essential business fundamentals and corporate details for Zentalis Pharmaceuticals, Inc. (ZNTL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 Apr 2020
Employees
166.00
Website
https://zentalis.comCEO
Julie M. Eastland
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
ZNTL Financial Timeline
Browse a chronological timeline of Zentalis Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.53.
Earnings released on 6 Aug 2025
EPS came in at -$0.37 surpassing the estimated -$0.56 by +33.93%.
Earnings released on 14 May 2025
EPS came in at -$0.67 matching the estimated -$0.67.
Earnings released on 26 Mar 2025
EPS came in at -$0.66 surpassing the estimated -$0.75 by +12.00%, while revenue for the quarter reached $26.87M .
Earnings released on 12 Nov 2024
EPS came in at -$0.56 surpassing the estimated -$0.92 by +39.13%.
Earnings released on 9 Aug 2024
EPS came in at -$1.24 falling short of the estimated -$0.83 by -49.40%.
Earnings released on 7 May 2024
EPS came in at $0.14 surpassing the estimated -$0.77 by +118.18%, while revenue for the quarter reached $40.56M , beating expectations by +209.15%.
Earnings released on 27 Feb 2024
EPS came in at -$0.83 surpassing the estimated -$0.92 by +9.78%, while revenue for the quarter reached $2.10M .
Earnings released on 6 Nov 2023
EPS came in at -$0.79 surpassing the estimated -$1.01 by +21.78%.
Earnings released on 9 Aug 2023
EPS came in at -$1.85 falling short of the estimated -$1.06 by -74.53%.
Earnings released on 10 May 2023
EPS came in at -$1.07 falling short of the estimated -$0.96 by -11.46%.
Earnings released on 1 Mar 2023
EPS came in at -$0.92 surpassing the estimated -$1.09 by +15.60%.
Earnings released on 9 Nov 2022
EPS came in at -$0.96 surpassing the estimated -$1.15 by +16.52%.
Earnings released on 9 Aug 2022
EPS came in at -$1.34 falling short of the estimated -$1.21 by -10.74%.
Earnings released on 5 May 2022
EPS came in at -$1.31 falling short of the estimated -$1.20 by -9.17%.
Earnings released on 24 Feb 2022
EPS came in at -$1.11 surpassing the estimated -$1.34 by +17.16%.
Earnings released on 10 Nov 2021
EPS came in at -$0.09 surpassing the estimated -$1.31 by +93.13%.
Earnings released on 12 Aug 2021
EPS came in at -$1.34 falling short of the estimated -$1.14 by -17.54%.
Earnings released on 17 May 2021
EPS came in at -$1.24 falling short of the estimated -$0.96 by -29.17%.
Earnings released on 25 Mar 2021
EPS came in at -$1.01 falling short of the estimated -$0.97 by -4.12%.
Earnings released on 9 Nov 2020
EPS came in at -$0.91 falling short of the estimated -$0.73 by -24.66%.
ZNTL Stock Performance
Access detailed ZNTL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.